CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Microlin Bio Inc. (OLD) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Microlin Bio Inc. (OLD)
135 East 57th Street
24th Floor
New York, NY  10022-2050  United States
Microlin Bio Inc. filed a Registration Withdrawal Request of its Form S-1 (File No. 333-192271) with the SEC on 9/19/2014. The Company is seeking withdrawal of the Registration Statement because of unfavorable market conditions.
This is a Subsidiary, click here for the Parent Company
Business Summary
MicroLin Bio, Inc. is a development-stage therapeutic and diagnostic company focusing on microRNA and its role in oncology. In addition, the Company is licensed a delivery technology for potential use in the development of its therapeutic product candidates. The Company intends to develop a series of miR-based AMT and MRT therapeutics and diagnostic microRNA panel tests (MPTs) for lung, ovarian, colorectal and prostate cancers. miR-21 and miR-17-5p are elevated in many types of cancer, Lumiralin and Colomiralin may be useful in treating multiple tumor types. MicroRNA-based therapeutics can be used in combination with each other in a common delivery vehicle.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20149/30/2013YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer JosephHernandez 7/30/2013 7/30/2013
President, Chief Financial Officer, Director Christopher P.Lowe 46
Chief Scientific Officer, Director Nicholas M.Dean 56
3 additional Officers and Directors records available in full report.

General Information
Stock Exchange: NASD
Federal Tax Id: 463896989


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023